KBC Group NV boosted its position in shares of Alkermes Plc (NASDAQ:ALKS) by 141.8% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 225,966 shares of the company’s stock after buying an additional 132,525 shares during the period. KBC Group NV’s holdings in Alkermes Plc were worth $13,219,000 as of its most recent SEC filing.
A number of other hedge funds have also recently added to or reduced their stakes in the stock. Massey Quick & Co. LLC purchased a new stake in Alkermes Plc during the fourth quarter worth about $111,000. Greenwood Capital Associates LLC purchased a new stake in Alkermes Plc during the fourth quarter worth about $202,000. Mn Services Vermogensbeheer B.V. boosted its stake in Alkermes Plc by 5.9% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 4,053 shares of the company’s stock worth $222,000 after buying an additional 224 shares during the last quarter. Decatur Capital Management Inc. purchased a new stake in Alkermes Plc during the first quarter worth about $267,000. Finally, Fiera Capital Corp boosted its stake in Alkermes Plc by 2.1% in the fourth quarter. Fiera Capital Corp now owns 5,516 shares of the company’s stock worth $307,000 after buying an additional 116 shares during the last quarter. 95.52% of the stock is owned by hedge funds and other institutional investors.
Alkermes Plc (NASDAQ:ALKS) traded down 0.03% during trading on Friday, reaching $57.91. The company’s stock had a trading volume of 728,646 shares. The company’s 50 day moving average price is $57.81 and its 200 day moving average price is $56.90. The company’s market cap is $8.87 billion. Alkermes Plc has a 52 week low of $39.65 and a 52 week high of $62.50.
Alkermes Plc (NASDAQ:ALKS) last posted its quarterly earnings data on Thursday, April 27th. The company reported ($0.31) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.07. Alkermes Plc had a negative return on equity of 12.75% and a negative net margin of 36.92%. The business had revenue of $191.80 million for the quarter, compared to analyst estimates of $195.79 million. During the same quarter in the prior year, the company earned ($0.16) earnings per share. The company’s quarterly revenue was up 22.3% on a year-over-year basis. On average, equities analysts anticipate that Alkermes Plc will post ($0.04) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://sportsperspectives.com/2017/05/20/kbc-group-nv-boosts-position-in-alkermes-plc-alks.html.
A number of analysts recently issued reports on the company. Credit Suisse Group AG set a $70.00 price objective on Alkermes Plc and gave the company a “buy” rating in a research report on Friday. Morgan Stanley reissued an “equal weight” rating and set a $62.00 price objective on shares of Alkermes Plc in a research report on Monday, April 24th. TheStreet raised Alkermes Plc from a “d+” rating to a “c” rating in a research report on Wednesday, February 15th. Cowen and Company reissued a “buy” rating on shares of Alkermes Plc in a research report on Friday, April 28th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $51.00 price objective on shares of Alkermes Plc in a research report on Thursday, February 16th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $63.55.
In other news, Director Richard F. Pops sold 50,000 shares of the stock in a transaction dated Wednesday, May 17th. The shares were sold at an average price of $58.19, for a total transaction of $2,909,500.00. Following the completion of the transaction, the director now directly owns 680,406 shares in the company, valued at approximately $39,592,825.14. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP James M. Frates sold 25,000 shares of the stock in a transaction dated Tuesday, March 7th. The stock was sold at an average price of $59.08, for a total transaction of $1,477,000.00. Following the transaction, the senior vice president now owns 144,053 shares of the company’s stock, valued at $8,510,651.24. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 199,800 shares of company stock valued at $11,638,101. Company insiders own 4.75% of the company’s stock.
Alkermes Plc Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes Plc and related companies with MarketBeat.com's FREE daily email newsletter.